5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

计划入组 35 人 · 首次发布于 2026 年 2 月 11 日

PD-1/PD-L1 Pathway Study on Septic Patients

计划入组 39 人 · 首次发布于 2010 年 7 月 14 日

Umbilical CB-NK Expressing sIL-15 & PD-L1 +/- Atezolizumab in NSCLC Pts Refractory to PD-1/PD-L1

计划入组 9 人 · 首次发布于 2025 年 7 月 8 日

engineered-PD-1-based PD-L1 inhibitor (cancer)

Engineered-PD-1-based PD-L1 inhibitor(Ligand)

PD-1/PD-L1 inhibitor vaccine (Theravectys SAS)

PD-RX Pharmaceuticals, Inc.

United States

Saul Centers Inc

United States

ACRES Commercial

United States

Anlotinib Combined with PD-1 Inhibitor Suppresses MSS Colorectal Cancer via Vascular Normalization and Immune Reprogramming

European Market Access Hurdles Loom for PD-1/PD-L1 Immunotherapies in Oncology

Phase 3 Trials Advance PD-1/PD-L1 Inhibitors for BCG-Naive NMIBC